Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Durvalumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Durvalumab as a study intervention. Browse Durvalumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
453
Shown on this page
12
Current sort
Recently updated
Therapy scope
Durvalumab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Durvalumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 229–240 of 453 matching trials for Durvalumab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 2 Interventional

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

NCT07174570
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure
Drug · Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 24, 2026, 3:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

NCT04781192
View directory record Official record
Conditions
Advanced Biliary Tract Cancer
Interventions
Durvalumab, Regorafenib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Overland Park, Kansas • Westwood, Kansas • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 24, 2026, 3:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

NCT03539822
View directory record Official record
Conditions
Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
Interventions
Cabozantinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
2
States / cities
Westwood, Kansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 24, 2026, 3:32 AM EDT
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 24, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

NCT06526104
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis, Liver
Interventions
Tremelimumab, Durvalumab
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 24, 2026, 3:32 AM EDT
Active, not recruiting Phase 3 Interventional

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Esophagogastric Junction
Interventions
Durvalumab, FLOT chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 200 Years
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sylmar, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 24, 2026, 3:32 AM EDT
Active, not recruiting Phase 3 Interventional

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036
View directory record Official record
Conditions
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Interventions
Tarlatamab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
37
States / cities
Mobile, Alabama • Los Angeles, California • New Haven, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 24, 2026, 3:32 AM EDT
Recruiting Phase 1 Interventional

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

NCT06546969
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma
Interventions
Gemcitabine, Cisplatin, Durvalumab, Spatially Fractionated RT, Deep Hyperthermia
Drug · Radiation · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 24, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

Impact of Circadian Rhythm on Immunotherapy

NCT07224971
View directory record Official record
Conditions
Advanced/Metastatic NSCLC
Interventions
Immunotherapy - PD-1 Blocker
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 24, 2026, 3:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab, Tucatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
10
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 24, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

NCT04430452
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
Durvalumab, Hypofractionated Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Mary Feng, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 24, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

NCT03381183
View directory record Official record
Conditions
Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
Interventions
Durvalumab, IRX-2 Regimen
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 24, 2026, 3:32 AM EDT

About this Durvalumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Durvalumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Durvalumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Durvalumab.